Market Intelligence, Clinical Progress, and High-Purity Reagents for Hippo Pathway and Regenerative Medicine Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LATS2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LATS2 Recombinant Protein (Kinase Domain / Full Length) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Sf9/Insect expressed for optimal phosphorylation status. |
View LATS2 Products |
| Gene Delivery | LATS2 Promise-ORF / Lentivirus Full-length ORF (WT and Kinase-Dead mutants like K655R) for stable cell line construction and Hippo pathway reporter assays. |
View LATS2 Products |
| Benchmark Ab | Anti-LATS2 Recombinant Antibody Recombinant positive control for western blot, immunoprecipitation, and intracellular flow cytometry. |
View LATS2 Products |
| Validator | LATS2 siRNA Set Target-specific knockdown verification in tumor suppressor or tissue regeneration assays. |
View LATS2 Products |
| Related Target A | LATS1 Highly homologous kinase. Critical for counter-screening to ensure compound selectivity or to validate dual LATS1/2 inhibitors. |
View LATS1 Products |
| Related Target B | YAP1 Primary downstream substrate of LATS2. Essential for downstream phosphorylation (p-YAP S127) and nuclear translocation readouts. |
View YAP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Selectivity (LATS1 vs LATS2) | High-purity recombinant LATS1 and LATS2 proteins available with verified sequence identity by mass spectrometry. |
| Physiological Conformation in Cells | Lentiviral vectors expressing full-length wild-type or mutant LATS2 to establish stable cell lines for functional YAP translocation assays. |
| Lack of Controls | Sequence-verified recombinant antibodies serving as reliable positive controls for endogenous LATS2 detection. |
| False Positives | Validated siRNA pools included to confirm target-specific phenotypic rescue or knockdown efficiency. |
Live LATS2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LATS2 therapeutics is intensifying, with major players shifting focus from traditional oncology targets to regenerative medicine and combination therapies. As first-generation Hippo pathway therapies reach the clinic, the next wave of R&D is targeting LATS1/2 inhibition for tissue regeneration and LATS2 reactivation strategies to overcome drug resistance in oncology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Vivace Therapeutics, Ikaria, Academic Consortia | Myocardial Infarction, Liver Regeneration, Wound Healing | Selectivity Assay (Need high-purity LATS1 & LATS2 Kinase Domain Proteins) |
| Gene Therapy / mRNA | Biotech Startups | Mesothelioma, YAP-driven Solid Tumors | Expression Validation (Need Lentivirus and high-specificity Antibodies) |
| Combination Therapies | Oncology Pharma | EGFR/KRAS Resistant Cancers | Pathway Modulation Assays (Need YAP1 & TEAD1 reference targets) |